410 related articles for article (PubMed ID: 34951565)
1. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
Zhao H; Lu L; Peng Z; Chen LL; Meng X; Zhang C; Ip JD; Chan WM; Chu AW; Chan KH; Jin DY; Chen H; Yuen KY; To KK
Emerg Microbes Infect; 2022 Dec; 11(1):277-283. PubMed ID: 34951565
[TBL] [Abstract][Full Text] [Related]
2. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
[TBL] [Abstract][Full Text] [Related]
3. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
5. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.
Hui KPY; Ho JCW; Cheung MC; Ng KC; Ching RHH; Lai KL; Kam TT; Gu H; Sit KY; Hsin MKY; Au TWK; Poon LLM; Peiris M; Nicholls JM; Chan MCW
Nature; 2022 Mar; 603(7902):715-720. PubMed ID: 35104836
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
8. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution.
Qu B; Miskey C; Gömer A; Kleinert RDV; Ibanez SC; Eberle R; Ebenig A; Postmus D; Nocke MK; Herrmann M; Itotia TK; Herrmann ST; Heinen N; Höck S; Hastert FD; von Rhein C; Schürmann C; Li X; van Zandbergen G; Widera M; Ciesek S; Schnierle BS; Tarr AW; Steinmann E; Goffinet C; Pfaender S; Locker JK; Mühlebach MD; Todt D; Brown RJP
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2407437121. PubMed ID: 38814864
[TBL] [Abstract][Full Text] [Related]
10. Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.
Padmanabhan P; Dixit NM
J Theor Biol; 2023 Sep; 572():111568. PubMed ID: 37393986
[TBL] [Abstract][Full Text] [Related]
11. Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
Guo W; Porter LM; Crozier TW; Coates M; Jha A; McKie M; Nathan JA; Lehner PJ; Greenwood EJ; McCaughan F
Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35110354
[TBL] [Abstract][Full Text] [Related]
12. A Cytopathic Effect-Based Tissue Culture Method for HCoV-OC43 Titration Using TMPRSS2-Expressing VeroE6 Cells.
Hirose R; Watanabe N; Bandou R; Yoshida T; Daidoji T; Naito Y; Itoh Y; Nakaya T
mSphere; 2021 May; 6(3):. PubMed ID: 33980675
[TBL] [Abstract][Full Text] [Related]
13. Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases.
Chaudhry MZ; Eschke K; Hoffmann M; Grashoff M; Abassi L; Kim Y; Brunotte L; Ludwig S; Kröger A; Klawonn F; Pöhlmann SH; Cicin-Sain L
J Virol; 2022 Mar; 96(5):e0218621. PubMed ID: 35019723
[TBL] [Abstract][Full Text] [Related]
14. Difference in TMPRSS2 usage by Delta and Omicron variants of SARS-CoV-2: Implication for a sudden increase among children.
Kakee S; Kanai K; Tsuneki-Tokunaga A; Okuno K; Namba N; Tomita K; Chikumi H; Kageyama S
PLoS One; 2024; 19(6):e0299445. PubMed ID: 38870131
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection.
Metzdorf K; Jacobsen H; Greweling-Pils MC; Hoffmann M; Lüddecke T; Miller F; Melcher L; Kempf AM; Nehlmeier I; Bruder D; Widera M; Ciesek S; Pöhlmann S; Čičin-Šain L
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851486
[TBL] [Abstract][Full Text] [Related]
16. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
Zhao H; To KKW; Lam H; Zhou X; Chan JF; Peng Z; Lee ACY; Cai J; Chan WM; Ip JD; Chan CC; Yeung ML; Zhang AJ; Chu AWH; Jiang S; Yuen KY
Nat Commun; 2021 Mar; 12(1):1517. PubMed ID: 33750821
[TBL] [Abstract][Full Text] [Related]
17. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.
Shuai H; Chan JF; Hu B; Chai Y; Yuen TT; Yin F; Huang X; Yoon C; Hu JC; Liu H; Shi J; Liu Y; Zhu T; Zhang J; Hou Y; Wang Y; Lu L; Cai JP; Zhang AJ; Zhou J; Yuan S; Brindley MA; Zhang BZ; Huang JD; To KK; Yuen KY; Chu H
Nature; 2022 Mar; 603(7902):693-699. PubMed ID: 35062016
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
19. Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.
Iwata-Yoshikawa N; Kakizaki M; Shiwa-Sudo N; Okura T; Tahara M; Fukushi S; Maeda K; Kawase M; Asanuma H; Tomita Y; Takayama I; Matsuyama S; Shirato K; Suzuki T; Nagata N; Takeda M
Nat Commun; 2022 Oct; 13(1):6100. PubMed ID: 36243815
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
